Skip to content
Tuesday 11 August 2026London --:--Frankfurt --:--Zurich --:--
NewslettersSearchEN · DE
MorningWire

European business, markets and politics

FTSE 100
10,862.50
-0.35%
DAX
26,323.88
0.00%
CAC 40
8,726.03
0.00%
STOXX 50
6,535.62
0.00%
  • Europe
  • Markets
  • Business
  • Economy
  • Technology
  • Politics
  • Opinion
More
GermanyFranceBankingAIEnergyFintechPropertyCapital Markets
  • Germany
  • France
  • Europe
  • Markets
  • Business
  • Economy
  • Technology
  • Politics
  • Opinion
  • DE
What is City Talk? City Talk allows marketers to connect directly with our audience by publishing content on morningwire.eu
Tuesday 11 October 2022 5:02 am  |  Updated:  Tuesday 11 October 2022 3:08 pm

Diabetes and sight loss in Nepal

By: Vision and Eye Institute - Anglia Ruskin University

Add as a preferred source on Google

Professor Shahina Pardhan, Director of the Vision and Eye Research Institute at the Anglia Ruskin University writes about diabetes and sight loss in Nepal.

Diabetic-related blindness is one of the leading causes of vision loss worldwide. It is largely
preventable with good diabetes control and regular retinal screening. People from Asian backgrounds including Nepali people have a significantly higher risk of diabetes compared to Caucasians. Anglia Ruskin University’s Vision and Eye Research Institute (VERI) has shown that the risk of diabetic-related blindness is also high in these patients.

Researchers developed a study aimed at identifying the barriers to good diabetes control in a local
population in Nepal, providing education and empowering people to improve their health outcomes.

Our study, using a questionnaire to gather data on awareness about diabetes control, self-help and
lifestyle in 200 patients, showed that patients who were at a higher risk of uncontrolled diabetes and therefore increased risk of blindness also showed reduced health literacy and poor treatment compliance.

Although patients self-reported that their diabetes was adequately controlled, and clinical tests showed high blood sugar levels in these patients. Informed of our research findings, a brainstorming meeting with 25 people was held in Pokhara in 2018 to develop a training programme for diabetic patients. Participants included representatives of Diabetes and Endocrinology Association of Nepal (DEAN) and the Nepal Health Research Council, diabetic patients, and healthcare providers including a diabetes doctor, a dietician, an ophthalmologist, a physical activity instructor, and a behaviour change worker.

Diabetes-awareness training, culturally appropriate to the Nepali context, was developed in the local language, to address the barriers identified by the research. The Nepalese Association of Optometrists are keen to roll out the training programme via its outreach activities to remote villages.

Since 2018, the Diabetes, Thyroid and Endocrine Care Centre in Pokhara have used our training
programme to improve awareness for all their diabetic patients attending clinics. The training has already benefited over 40,000 diabetic patients, of whom 89% requested retinal screening compared to 28% prior to the training. A randomised clinical trial has also been set up in collaboration with Pardhan’s team. Preliminary data shows that 98% of patients in the intervention group requested a diabetic
retinal check within three months, compared to 36% in the control group.

Publications

Sapkota RP, Upadhyaya T, Gurung G, et al Need to improve awareness and treatment compliance in high-risk patients for diabetic complications in Nepal BMJ Open Diabetes Research and Care 2018;6:e000525. doi: 10.1136/bmjdrc-2018-000525 https://drc.bmj.com/content/6/1/e000525

Dr Raju Sapkota Interventions to control diabetes and improve attendance for retinopathy screening in Kaski, Tanahun and Syangja districts of Nepal: a randomised controlled trial https://www.isrctn.com/ISRCTN10990062

The Tej Kohli & Ruit Foundation is a restricted fund operating under the auspices of Prism The Gift Fund, registered UK charity number 1099682.

Read more

Dompé Doses First Patient in Phase 3 Study of Cenegermin-bkbj in NAION

Share this article

  • Facebook
  • X
  • LinkedIn
  • WhatsApp
  • Email

Similarly tagged content:

Sections

  • Life&Style

Categories

  • Morning Wire Content
  • Charity

Trending Articles

  • Nottingham Forest owner Marinakis sues Crystal Palace for defamation

  • Back to basics: Sainsbury’s gradual retreat from the British high street

  • Hargreaves Lansdown orders staff back to office

  • As it happened: Intel, Arm shares slide; Oil climbs higher

  • Thames Water faces fresh threat to survival after pensions regulation breach

More from Morning Wire

  • Dompé Doses First Patient in Phase 3 Study of Cenegermin-bkbj in NAION

    Business Wire
  • Insulet Partners with Calm to Bring Mindfulness and Well-Being Tools to the Diabetes Community, Featuring a New Sleep Story Narrated by Lila Moss

    Business Wire
  • Tenpoint Therapeutics Announces United Kingdom Submission of Marketing Authorization Application to the Medicines and Healthcare Products Regulatory Agency (MHRA) for the Treatment of Blurry Close-Up Vision (Presbyopia) in Adults

    Business Wire
  • Verdiva Bio Initiates Phase 1 Study of VRB-103, a Selective Oral Amylin Peptide Analog With Weekly Dosing Potential

    Business Wire
  • Fine dining and The Jab: A Michelin dinner with the Ozempic set

    Life&Style
    Ozempic tablet on a plate highlighting medications role in weight loss and diabetes management in healthcare news.
  • Leeds NHS Innovation to Accelerate Global Adoption of AI-enabled Pathology for Cancer Diagnostics Through Epredia Partnership

    Business Wire
  • Everseen Acquires Viztel Portfolio from RadiusAI, Extending Its Vision AI Platform from Checkout to Full-Store Intelligence

    Business Wire
  • New Smarsh Research Finds Enterprises Are Deploying AI Faster Than They Can Govern It

    Business Wire
MorningWire

Independent European business, markets and political news for decision-makers.

Morning Briefing

Europe

  • Germany
  • France
  • Europe
  • UK & Ireland

Business

  • Markets
  • Banking
  • Technology
  • Energy
  • Property
  • Fintech

Editorial

  • Opinion
  • Editorial Policy
  • Corrections
  • Contact

Company

  • About Morning Wire
  • Privacy Policy
  • Terms of Use
  • Cookie Policy
© 2026 Morning Wire Ltd · Published by Morning Wire Media, Bahnhofstrasse 65, 8001 Zürich, Switzerland
Privacy · Terms · Cookies · Facebook